Advancing Influenza Vaccine Development: Sino Biological Launches Antigens For The 2026-2027 Northern Hemisphere Influenza Vaccine Strains

The World Health Organization (WHO) has announced its recommendations for nan 2026–2027 Northern Hemisphere influenza vaccine composition. The update highlights 2 cardinal developments: nan continued dispersed of A (H3N2) subclade K and nan increasing circulation of new B/Victoria lineage strains. In accelerated response, Sino Biological, Inc., a world leader successful recombinant technology, has launched a broad sheet of antigens for nan 2026-2027 Northern Hemisphere influenza vaccine strains to accelerate influenza vaccine development.

Decoding nan 2026-2027 Northern Hemisphere influenza vaccine strains

Since its indentification successful August 2025, H3N2 subclade K (J.2.4.1) has go nan ascendant influenza A strain worldwide. Defined by the T135K and S144N mutations, this strain exhibits enhanced immune escape, prompting WHO’s action of A/Darwin/1454/2025 (egg-based, cell-based) as nan caller H3N2 reference viruses. The H1N1 constituent has been updated to A/Missouri/11/2025 (egg-based, cell-based).

Alongside H3N2, influenza B activity is rising sharply. In regions specified arsenic Hong Kong and nan U.S., nan proportionality of B/Victoria lineage viruses precocious accrued from 6 % to complete 20 %. These trends led WHO to recommendations B/Tokyo/EIS13-175/2025 (egg-based) and B/Pennsylvania/14/2025 (cell-based) strains for nan upcoming season.

Sino Biological’s broad reagents for 2026-2027 influenza vaccine research

To support world influenza vaccine investigation and development, Sino Biological has launched an extended portfolio of recombinant antigens for nan 2026-2027 Northern Hemisphere influenza vaccine strains, spanning cardinal viral antigens including Hemagglutinin (HA), Neuraminidase (NA), and Nucleoprotein (NP). These include:

• H1N1 reagents: A/Missouri/11/2025 (H1N1) HA Trimer (HEK293 cell-expressed, purity ≥ 90 % verified by SEC-MALS, activity validated by ELISA), NA, and NP antigens are disposable now.
• H3N2 subclade K proteins: Recombinant HA, NA, NP aligned pinch A/Darwin/1454/2025 - disposable now.
• Influenza B reagents: In improvement for B/Tokyo/EIS13-175/2025 and B/Pennsylvania/14/2025.
• Stable HA Trimers: High-purity, SEC-MALS–validated trimeric HA maintaining autochthonal conformation for meticulous immune characterization.

Our ngo is to supply nan technological organization pinch nan highest value devices arsenic quickly arsenic imaginable erstwhile infectious illness improvement threatens world wellness preparedness, Sino Biological remains committed to delivering reliable reagents that beforehand world influenza preparedness and vaccine innovation."

Dr. Rob Burgess, Chief Business Officer, Sino Biological US